Positron emission tomography-computed tomography (PET-CT) can identify bony lesions, assess disease burden, and detect extramedullary disease (EMD) in patients with multiple myeloma. We retrospectively reviewed records of patients who underwent PET-CT within 60 days 
| INTRODUCTION
Multiple myeloma is a plasma cell proliferative disorder that accounts for approximately 10% of all hematologic malignancies. 1 Because a diagnostic characteristic of the disease is bony involvement, detection of these lesions is of paramount importance. Conventional radiographic skeletal surveys have been the standard imaging modality for screening and staging of patients with newly diagnosed multiple myeloma. More recently, advanced imaging techniques such as magnetic resonance imaging, positron emission tomography-computed tomography (PET-CT), and whole-body computed tomography (CT) were shown to be superior to conventional (radiographic) skeletal surveys (CSS) for detecting bony lesions. 2, 3 Previous studies [4] [5] [6] have also shown that extramedullary disease (EMD), detected by different modalities, had negative prognostic value. Therefore, PET-CT is considered an important imaging modality in patients with newly diagnosed multiple myeloma
Abbreviations: CSS, conventional (radiographic) skeletal survey; CT, computed tomography; EMD, extramedullary disease; FISH, fluorescence in situ hybridization; FL, focal lesion; HRA, high-risk abnormality; IMid, immunomodulatory agent; OS, overall survival; PCPI, plasma cell proliferative index; PET-CT, positron emission tomography-computed tomography; PFS, progression-free survival; PI, proteasome inhibitor; SUV max , maximum standardized uptake value.
because it can identify bony lesions, assess disease burden, and detect EMD. 2, [7] [8] [9] [10] [11] [12] Moreover, it has value when assessing treatment response. 13 The International Myeloma Working Group recommends integrating PET-CT (as a novel imaging technique) in the assessment of newly diagnosed patients. 4, 14 However, data regarding the prognostic value of PET-CT in the newly diagnosed setting remains limited, particularly in the era of therapy that includes so-called novel agents and current standard combinations. Here, we report the nature and prognostic impact of PET-CT abnormalities in a contemporary cohort of patients with newly diagnosed multiple myeloma who received treatment with novel agents.
| PATIENTS AND METHODS
The study was approved by the Mayo Clinic Institutional Review Board, and all the patients consented to have their medical records reviewed according to institutional review board practices.
| Patients
We retrospectively evaluated patients with newly diagnosed multiple myeloma who were seen at Mayo Clinic (Rochester, MN), from April 
| Statistical analysis
Statistical analysis was performed with JMP software (SAS Institute 
| RESULTS
We identified and included 313 patients in the analysis. P = .82), nor was the percentage of abnormally low levels (defined as <3.5 g/dL) (41% vs. 38%; P = .56). The median β 2 -microglobulin levels and the proportion of patients with high levels (≥3.5 mcg/mL) were not significantly different among patients with and without EMD (3.9 vs. 3.5 mcg/ mL [P = .08] and 60% vs. 52% [P = .37], respectively).
| Correlation with laboratory biomarkers
Two hundred and five patients (65%) had a PCPI test at the time of
diagnosis. An elevated PCPI, defined as 2% or greater, was associated with worse OS (77 vs. 35 months; P < .001). Elevated PCPI was significantly more common in patients with 3 or more FLs vs. less than 3 FLs (24% vs. 10%; P = .02). Similarly, more patients with EMD had an elevated PCPI (39% vs. 16% for those with and without EMD, respectively; P = .02).
| Correlation with cytogenetic abnormalities
Two hundred and fourteen patients (68%) had data from FISH tests performed at the time of diagnosis (68%). Forty-seven patients (22%)
had HRAs. Presence of HRA was associated with inferior median OS (40.7 vs. 66.5 months for patients with and without HRAs, respectively; P = .006). The number of FLs was not predictive of HRA (24% vs. 19% of patients with and without ≥3 FL, respectively, had HRAs; P = .50), nor was the presence of EMD predictive (26% vs. 21% for patients with and without EMD, respectively; P = .62).
| Treatment regimens
The percentages of patients receiving a combination of proteasome inhibitor (PI) and immunomodulatory agent (IMid), PI-based regimen,
IMid-based regimen, and alkylator-based regimen were 25%, 32%, 36% and 1%, respectively. We did not observe any significant differences in the induction regimen administered to those with 3 or more FLs vs. those with fewer than 3 FLs (P = .18) or among those with and without EMD (P = .78). One hundred twenty-nine patients (43%) had an autologous stem cell transplant, with no significant difference between the FL groups (P = .48) or EMD groups (P = 1.0).
| Comparison with CSS
Two hundred and fourteen patients had a CSS and underwent PET-CT at the time of diagnosis. Sixty-seven patients (31%) had no bony lytic lesions detected with either imaging technique. One hundred and ten (51%) had lytic or lucent lesions observed with CSS; of these, 7 (3%) had lytic lesions seen with CSS only and not with PET-CT.
Among those seven patients, six had focal lesions on PET CT without being called lytic and one patient had lytic lesions in the calvarium by CSS not identified by PET. The data has been included. In 37 patients (17%), lytic bone lesions were seen with PET-CT only and not with CSS (P < .001); these findings suggest that PET-CT was considerably more sensitive than CSS for detecting lytic lesions. Table 2 summarizes the baseline imaging characteristics. Presence of ≥3 FLs predicted worse median OS ( Figure 1A) . OS from first-line therapy was significantly longer for patients with <3 FLs (median, 88.6
| Prognostic significance of PET-CT lesions
vs. 56.8 months; P = .005). The median PFS also was greater for patients with <3 FLs ( Figure 1B) . Presence of EMD was associated with shorter median OS but not PFS ( Figure 1C,D) . No SUV max cutoff value was predictive of PFS or OS. On multivariable analysis, elevated PCPI was the only independent predictor of PFS, whereas elevated PCPI and HRA were predictive of OS.
| Univariable and multivariable analyses

| DISCUSSION
An ideal staging test provides highly accurate information that is subject to minimal interobserver variation, and it should further provide insights into tumor behavior and prognosis. Advanced imaging techniques have essentially replaced CSSs in the diagnostic evaluation and staging of patients with newly diagnosed multiple myeloma. However, commonly used prognostic models and risk-adapted treatment strategies 15 are solely based on laboratory findings. 16, 17 Our study highlights a number of important points with respect to PET-CT imaging in myeloma. First, 84% of patients assessed with PET-CT at diagnosis had an abnormality (eg, FL, lytic lesion, or EMD) identified with this imaging modality. This is in contrast to traditional CSS, which has a lower sensitivity for detecting bony lesions and lacks the ability to confidently detect EMD. Furthermore, our data confirm previous observations that noted that the multiple myeloma diagnosis could be missed in patients who undergo only a CSS. In our study, elevated PCPI and HRA were the only independent markers that were predictive of OS on multivariable analysis; this finding might be explained by the association between the PET-CT findings and these laboratory markers. Associations between various SUV max cutoffs and prognosis have been suggested in previous studies, 5, 6, 20 but in the current study, we did not identify a clear SUV max cutoff that was associated with an inferior PFS or OS. However, these results need to be interpreted with caution because the SUV max was reported for only 42% of patients.
Our study was limited by the biases that are inherent to a retrospective review. Patient selection for PET-CT scanning was not uniform and was determined by physician discretion or preference; the resulting select study population may have affected our results. Not all PET-CT imaging was performed at our institution and according to our protocols, although most non-Mayo images were reviewed by radiologists at our institution. In addition, although all scans were reviewed at our institution, the assessments were not controlled, nor was a specific protocol used; interreporter variability therefore may have affected our results. This lack of uniformity was particularly notable in documentation of the SUV max because these data were missing for a considerable proportion of patients. The lack of standardized assessment has been a consistent theme among other studies of PET-CT imaging in myeloma and attempts are being made to establish standard interpretation criteria. 22 Despite these limitations, we have shown that PET-CT is a valuable tool for assessing disease burden and could provide prognostic information about a contemporary cohort of patients with newly diagnosed myeloma who received treatment with predominantly newer agents. Further prospective studies are needed to ascertain the role of PET-CT in risk-stratifying patients at the time of diagnosis and further informing decision-making. 
